This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sun, X.-F. Articles by Nordenskjöld, B. Search for Related Content PubMed PubMed Citation Articles by Sun, X.-F. Articles by Nordenskjöld, B. Social Bookmarking                            What's this?

Expression of the Deleted in Colorectal Cancer Gene Is Related to Prognosis in DNA Diploid and Low Proliferative Colorectal Adenocarcinoma

From the Divisions of Oncology and Cell Biology, Department of Biomedicine and Surgery, Linköping University, Linköping, Sweden.

Address reprint requests to Xiao-Feng Sun, MD, PhD, Division of Oncology, Department of Biomedicine and Surgery, Linköping University, S-581 85 Linköping, Sweden; email xisunonk{at}epost.liu.se

PURPOSE: Whether or not the deleted in colorectal cancer (DCC) gene is implicated in metastases or in predicting prognosis in patients with colorectal cancer has not previously been substantiated. Our aims were to investigate DCC expression in primary colorectal cancers and in metastases to identify any prognostic significance.

PATIENTS AND METHODS: DCC expression was examined immunohistochemically in 195 primary colorectal adenocarcinomas and in 23 paired primary tumors and lymph node metastases. DNA content and S-phase fraction were measured by flow cytometry.

RESULTS: The absence of DCC expression was observed in 55 primary tumors (28%). DCC negativity was significantly related to poor prognosis in patients with DNA diploid tumors (P = .03) and those with a low S-phase fraction (< 5%, P = .02) but not in patients with nondiploid tumors or those with a higher S-phase fraction. Furthermore, DCC expression retained its prognostic significance in the diploid subgroup after adjusting for sex, age, site, stage, growth pattern, and differentiation (P = .01). DCC expression was similar in primary tumors and their metastases.

CONCLUSION: The absence of DCC predicted a poor outcome in the patients with diploid tumors and those tumors with a low S-phase fraction. Immunohistochemistry may be considered as a practical test to assess prognosis in this subgroup of patients.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				I Zlobec and A Lugli Prognostic and predictive factors in colorectal cancer Postgrad. Med. J., August 1, 2008; 84(994): 403 - 411. [Abstract] [Full Text] [PDF]

				Y. Jiang, G. Casey, I. C. Lavery, Y. Zhang, D. Talantov, M. Martin-McGreevy, M. Skacel, E. Manilich, A. Mazumder, D. Atkins, et al. Development of a Clinically Feasible Molecular Assay to Predict Recurrence of Stage II Colon Cancer J. Mol. Diagn., July 1, 2008; 10(4): 346 - 354. [Abstract] [Full Text] [PDF]

				I Zlobec and A Lugli Prognostic and predictive factors in colorectal cancer J. Clin. Pathol., May 1, 2008; 61(5): 561 - 569. [Abstract] [Full Text] [PDF]

				A Bamias, Z Yu, P. Weinberger, S Markakis, D Kowalski, R. Camp, D. Rimm, M. Dimopoulos, and A Psyrri Automated quantitative analysis of DCC tumor suppressor protein in ovarian cancer tissue microarray shows association with {beta}-catenin levels and outcome in patients with epithelial ovarian cancer Ann. Onc., December 1, 2006; 17(12): 1797 - 1802. [Abstract] [Full Text] [PDF]

				G. Y. Locker, S. Hamilton, J. Harris, J. M. Jessup, N. Kemeny, J. S. Macdonald, M. R. Somerfield, D. F. Hayes, and R. C. Bast Jr ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer J. Clin. Oncol., November 20, 2006; 24(33): 5313 - 5327. [Abstract] [Full Text] [PDF]

				C. Aschele, D. Debernardis, S. Lonardi, R. Bandelloni, S. Casazza, S. Monfardini, and L. Gallo Deleted in Colon Cancer Protein Expression in Colorectal Cancer Metastases: A Major Predictor of Survival in Patients With Unresectable Metastatic Disease Receiving Palliative Fluorouracil-Based Chemotherapy J. Clin. Oncol., September 15, 2004; 22(18): 3758 - 3765. [Abstract] [Full Text] [PDF]

				P. Mehlen and E. R. Fearon Role of the Dependence Receptor DCC in Colorectal Cancer Pathogenesis J. Clin. Oncol., August 15, 2004; 22(16): 3420 - 3428. [Abstract] [Full Text] [PDF]

				Y. Wang, T. Jatkoe, Y. Zhang, M. G. Mutch, D. Talantov, J. Jiang, H. L. McLeod, and D. Atkins Gene Expression Profiles and Molecular Markers To Predict Recurrence of Dukes' B Colon Cancer J. Clin. Oncol., May 1, 2004; 22(9): 1564 - 1571. [Abstract] [Full Text] [PDF]

				F. Graziano and S. Cascinu Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough? Ann. Onc., July 1, 2003; 14(7): 1026 - 1038. [Abstract] [Full Text] [PDF]

				P. M. Calvert and H. Frucht The Genetics of Colorectal Cancer Ann Intern Med, October 1, 2002; 137(7): 603 - 612. [Abstract] [Full Text] [PDF]

				X.-F. Sun p73 Overexpression Is a Prognostic Factor in Patients with Colorectal Adenocarcinoma Clin. Cancer Res., January 1, 2002; 8(1): 165 - 170. [Abstract] [Full Text] [PDF]